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Key points
• Myeloma cells produce ammonium in the presence of glutamine, showing high Glutaminase and low Glutamine Synthetase expression.
• Myeloma cells show high expression of glutamine transporters and inhibition of ASCT2 transporter hinders myeloma growth.
Abstract
The importance of glutamine (Gln) metabolism in multiple myeloma (MM) cells and its potential role as a therapeutic target are still unknown, although it has been reported that human myeloma cell lines (HMCLs) are highly sensitive to Gln depletion. In this study, we found that both HMCLs and primary bone marrow (BM) CD138
+ cells produced large amounts of ammonium in the presence of Gln. MM patients have lower BM plasma Gln with higher ammonium and glutamate than patients with indolent monoclonal gammopathies. Interestingly, HMCLs expressed Glutaminase (GLS1) and were sensitive to its inhibition, while exhibited negligible expression of Glutamine Synthetase (GS). High GLS1 and low GS expression were also observed in primary CD138 + cells. Gln-free incubation or treatment with the glutaminolytic enzyme L-Asparaginase depleted the cell contents of Gln, glutamate and the anaplerotic substrate 2-oxoglutarate, inhibiting MM cell growth.
Consistent with the dependence of MM cells on extracellular Gln, a gene expression profile analysis, on both proprietary and published datasets, showed an increased expression of the Gln transporters SNAT1, ASCT2, and LAT1 by CD138 + cells across the progression of monoclonal gammopathies. Among these transporters, only ASCT2 inhibition in HMCLs caused a marked decrease in Gln uptake and a significant fall in cell growth. Consistently, stable ASCT2 downregulation by a lentiviral approach inhibited HMCL growth in vitro and in a murine model. In conclusion, MM cells strictly depend upon extracellular Gln and show features of Gln addiction.
Therefore, the inhibition of Gln uptake is a new attractive therapeutic strategy for MM.
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INTRODUCTION
Multiple Myeloma (MM) is characterized by the accumulation of malignant plasma cells (PCs) into the bone marrow (BM). 1, 2 It is a historical notion that the growth of MM cells was limited by depletion of L-glutamine (Gln) 3 and that MM cells may produce an excess of ammonium (NH 4 + ). 4, 5 Hyperammonemia with or without the related encephalopathy has been reported as a possible rare clinical manifestation in relapsed/refractory MM patients with high mortality rate. [6] [7] [8] [9] [10] [11] [12] Recently, multivariate analysis based on 1 H-NMR spectroscopy analysis of serum samples has shown that a specific metabolic profile characterized MM patients versus healthy controls, including Gln levels significantly lower in the MM group. 13 Overall, these data suggest that Gln is highly metabolized in MM cells. To satisfy metabolic requirements of Gln, mammalian cells rely on Glutamine Synthetase (GS), the enzyme that obtains Gln from glutamate (Glu) and NH 4 + . 14, 15 Moreover, a variety of carriers, operate Gln influx, such as the Na + -dependent transporters SNAT1-2 and ASCT2, and the Na + -independent transporter LAT1. 16 Gln is a substrate of several enzymes, playing an important role in various processes, such as the synthesis of nucleotides, other amino acids, or glucosamine. 17, 18 Moreover, through the activity of Glutaminases (GLS1 and GLS2), which hydrolyze the amide group obtaining NH 4 + and Glu, Gln may fuel the intracellular pool of the Krebs cycle intermediate and anaplerotic substrate 2-oxoglutarate (2-OG, α -ketoglutarate). 17, 18 Some types of human tumor cells exhibit an high requirement for Gln ("glutamine addiction") 15 and use large amounts of the amino acid as an anaplerotic substrate. [19] [20] [21] A number of metabolic features have been described in Gln addicted cancer cells, such as high GS expression 22 or high expression and/or activity of Gln transporters, such as ASCT2. 23 In Gln-addicted cancers, GLS1
inhibition, Gln transporter silencing, inhibitors of Gln uptake or Gln-depleting treatments lead to delayed or arrested tumor growth. [24] [25] [26] Gln depletion produces a severe metabolic stress and cell death in some types of acute myeloid leukemia (AML) 27, 28 and in Gln-addicted lymphoid cells. 29 Moreover, L-Asparaginase (ASNase), the mainstay in the treatment of acute lymphoblastic leukemia (ALL), 30, 31 hydrolyzes not only asparagine but also Gln, and Gln depletion is the main biochemical mechanism underlying the growth inhibition by ASNase in asparagine synthetase- del and/or 1q21 gain. 33, 34 A total cohort of 9 controls (patients without monoclonal gammopathy with cardiac disease; median age: 58 years; range: 42-72) underwent cardiac surgery and were included in the study to obtain normal PCs.
PATIENTS, MATERIALS AND METHODS

Patients
The University of Parma institutional review board (Parma, Italy) approved all the study protocols.
All of the patients and controls included in the study gave their written informed consent as laid down in the Declaration of Helsinki.
BM aspirates (5+5 mL, treated with EDTA to prevent clotting) were obtained from the iliac crest of 39 Analysis of the transcriptional profile of glutamine transporters
The analysis of the transcriptional profile of glutamine transporters was described in Supplementary Materials and Methods.
Real time-PCR analysis
Total cell RNA (1 μ g), isolated with GenElute™ total RNA Miniprep Kit (Sigma-Aldrich), was reverse transcribed as described. 25 Gln-related enzyme and transporter mRNA expression was analyzed by real-time PCR with the primers reported in Table S2 . Data analysis was made according to the Relative Standard Curve Method. 42 The mRNA expression of GAC and KGA was evaluated by taqman gene assay (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) by the probes hs01022166_m1 and hs01014019_m1, respectively.
Glutamine uptake
The influx of Gln was measured in RPMI 8226 cells following the method for amino acid transport determination previously described.
43
Liquid chromatography tandem mass spectrometry (LC-MS/MS)
Cells were seeded in a 6-well plate. After 24 h, growth medium was substituted with fresh medium with or without Gln (4 mM). 
Immunoblotting
Immunoblotting analysis was performed as previously described. 35 Blots were incubated at 4 °C overnight with the following antibodies: anti-β-actin (mouse, monoclonal, 1:5000, Sigma-Aldrich) 
Lentiviral infection and ASCT2 knockdown
Lentivirus short hairpin RNA (shRNA) anti-SLC1A5 (Origene, Rockville, MD) was used for ASCT2 stable knockdown in RPMI 8226 and JJN3 cell lines, whereas the scramble lentiviral vector was used as control. Recombinant lentivirus was produced by transient transfection of 293T cells following a standard protocol. HMCLs were infected as previously described, 35 and the efficiency of the infection was evaluated as % of positive cells for green fluorescence protein (GFP) signal by flow cytometry.
In vivo experiments
Severe combined immunodeficiency/non obese diabetic (SCID-NOD) mice (Harlan Laboratories, Udine, Italy) were housed under specific pathogen-free conditions. All procedures involving animals were performed in accordance with the National and International current regulations. 8
For personal use only. on July 26, 2016. by guest www.bloodjournal.org From mice for group were injected subcutaneously with 5x10 6 JJN3 cells stably transfected with anti-SLC1A5 containing plasmid vectors (ΔASCT2) or with the empty vector (Scramble). Tumor growth was monitored at different time points, and 21 days after inoculation mice were sacrificed and autopsies performed. Tumor mass was measured as previously described. 45 Plasmacytomas obtained from tumors removed from mice injected with JJN3 anti-SLC1A5 or JJN3 scramble were either fixed in 10% neutral buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin, or lysed for protein extraction and western blot analysis.
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RESULTS
Myeloma cells produce NH 4 + from glutamine
Firstly, we assessed the NH 4 + production by several HMCLs (RPMI 8226, OPM2, JJN3, KMS-12-BM, and XG1) and found that all these lines markedly increased NH 4 + output in the presence of Gln ( Figure 1A ). Conversely, the ALL 697 cell line did not ( Figure 1A ). Primary BM CD138 + PCs from MM patients produced higher NH 4 + than BM CD138 -cell fraction from the same patients, as shown for 10 representative MM patients (Mann-Whitney test, P=.0002 in the presence of Gln, Figure 1B ). NH 4 + production was Gln-dependent (P<.0001 for CD138 + fraction, Figure 1B ).
Comparing NH 4 + production between HMCLs and primary CD138 + PCs, we found that the Glndependent NH 4 + production was higher in HMCLs (P=.0027, Figure 1B ). Interestingly, we found 
Higher NH 4 + levels characterized MM patients as compared to SMM and MGUS
We screened both PB and BM NH4 + levels in subgroups of MM patients and controls. Among 21
MM out of the total cohort of patients enrolled in the study, we showed that 38% of them had high PB NH 4 + levels (standard limits 10-50 µmol/L) and 14% showed neurological symptoms of encephalopathy without signs of liver dysfunction. In the BM plasma, NH 4 + levels were significantly higher in patients with active MM as compared with MGUS and SMM (P=.042) ( Figure 1C ).
Patients with adverse FISH showed significantly higher BM NH 4 + levels than the others (median levels 163 µmol/L versus 93.5 μ mol/L; P=.006). Interestingly, BM plasma of MM patients had lower
Gln and higher Glu as compared with that of MGUS and SMM patients ( Figure 1D and 1E), pointing to glutaminase activity as the responsible of NH 4 + production. Amino acid profile in BM plasma is reported in Table S3 .
On the other hand, no significant correlation between the NH 4 + levels and % of BM PCs was found
=0.1588, P=NS) (data not shown). This observation was further confirmed in another
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MM cells express high levels of Glutaminase but not of Glutamine Synthetase
The expression of the two main enzymes responsible for Gln metabolism, Glutaminase-1 (GLS1)
and Glutamine Synthetase (GS), was evaluated in five HMCLs and in the ALL 697 cells ( Figure   2A ). Among the five HMCLs, XG1 had the highest expression of GLS1 (total, KGA, GAC), while the other four cell lines expressed GLS1 mRNAs at levels comparable with those exhibited by ALL cells. Total GLS1 expression and that of the two isoforms GAC and KGA were also detected in primary BM CD138 + cells purified from patients with different monoclonal gammopathies, without any significant difference among the groups ( Figure 2B ). Comparable levels of GLS1 mRNA were found in normal PCs (data not shown). On the contrary, GLS2 is expressed at very low levels in both HMCLs and primary MM cells ( Figure S1 ). The mRNA of GLUL, the gene that encodes for GS, was much less expressed in the five HMCLs than in 697 cells (Figure 2A ). HMCLs, with the exception of JJN3 cells, expressed ASNS, the gene for Asparagine Synthetase, at higher levels than 697 ALL cells ( Figure 2A ).
All the HMCLs tested showed similar levels of GLS1 protein, with two clearly detectable enzyme bands (the higher for native KGA and the lower for the cleaved form GAC) ( Figure 2C ). On the contrary, GS was not detectable in HMCLs but was readily found expressed in 697 cells ( Figure   2C ). Consistent with mRNA data, ASNS was present in the lysates of all the HMCLs tested at levels comparable (JJN3) or higher than those expressed by ALL 697 cells ( Figure 2C ). In several cell models, the abundance of GS (protein) is inversely correlated with Gln availability; [46] [47] [48] therefore, it is expected that GS will increase when cells are incubated under conditions of Gln shortage. However, even upon incubation in the absence of Gln, GS remained undetectable in HMCLs, while it was much more expressed in Gln-starved ALL cells compared with Gln-fed counterparts ( Figure 2D ).
GLS1 expression (both KGA and GAC) was also clearly evident in all but one lysates of CD138 + cells from SMM, ND-MM and R-MM patients ( Figure 2E ). Conversely, GS expression was barely or not detectable at all in the same samples ( Figure 2E ). 
MM cells are dependent on extracellular glutamine and use glutamine for anaplerosis
The high expression detected in MM cells prompted us to evaluate the effects of GLS1 inhibition on cell viability. The GLS1 inhibitor BPTES 49 significantly lowered cell viability in all the HMCLs tested ( Figure 3A) , with an effect ranging from 30% for JJN3 to 70% for XG1 cells at the highest dose tested (40 µM). Another GLS1 inhibitor, CB-839 (0.125-1 µM), markedly suppressed viability in RPMI 8226 cultures, while it had only small effects in OPM2, KMS-12-BM and XG1 cells and was ineffective in JJN3 cells ( Figure 3B ).
The low levels of GS expression detected in MM cells support the hypothesis that MM Gln metabolism depends on the availability of the extracellular amino acid. Indeed, when incubated in media at decreasing levels of Gln, HMCLs exhibited a progressive loss of viability; in the absence of the amino acid, viability suppression was complete for RPMI 8226, OPM2 and XG1 lines and >90% for JJN3 and KMS-12-BM cells ( Figure 3C ). Methionine-sulfoximine (MSO), an irreversible inhibitor of GS, had no effect, thus excluding a protective role of GS in MM cells ( Figure 3C ).
In order to understand the mechanism involved in the loss of viability of MM cells upon Gln depletion, we tested if Gln had an anaplerotic role in MM cells. To this aim, the intracellular levels of Gln, Glu, and 2-oxoglutarate (2-OG) were measured with mass spectrometry ( Figure 3D ), demonstrating that Gln-free incubation caused a substantial decrease of the three metabolites. A marked depletion of intracellular Glu and 2-OG, along with an increase of intracellular Gln, was also observed upon cell treatment with the GLS1 inhibitors BPTES and CB-839 ( Figure S2 ). As shown in Figure 3E , Gln depletion caused a significant increase in the percentage of apoptotic cells (P=.014) which was partially mitigated in the presence of a membrane-permeant form of 2-OG ( Figure 3E ). The anaplerotic role of Gln in MM cells and the related protection by 2-OG were confirmed incubating RPMI 8226, OPM2, JJN3, KMS-12-BM and XG1 cells under conditions of Gln repletion or depletion in the absence or in the presence of 2-OG ( Figure 3F ). In all the HMCLs, the anaplerotic substrate partially rescued cell viability from the effects of Gln depletion ( Figure 3F ).
For 
MM cells and HMCLs overexpressed glutamine transporters
The dramatic effect of extracellular Gln depletion and ASNase on MM cell viability suggests that the transport of Gln from the extracellular compartment is essential for MM cells. Gln uptake is due to several transporters in human cells. 23 Therefore, the gene expression profiles of some selected Gln transporters were evaluated in two independent PC dyscrasia datasets, both obtained either from proprietary or publicly available databases, including highly purified PC samples throughout the different MM disease phases from the pre-malignant monoclonal gammopathy up to PCL patients, besides healthy donors and HMCLs.
Among the Gln transporters, three carriers known to mediate Gln influx, the Na + -independent transporter LAT1 and the Na + -dependent transporters SNAT1 and ASCT2, coded by SLC7A5, SLC38A1 and SLC1A5, respectively, showed a significantly increasing trend in expression levels Two other amino acid transporters, not directly responsible for Gln uptake, also showed significant changes in both the datasets. In particular, xCT (SLC7A11) increased from normal PCs to HMCLs.
Conversely, y+LAT1 (SLC7A7), the low expression of which has been recently described as associated to favorable outcome, 50 had an opposite trend (Figures 5A and 5B, Tables S3 and S4 ).
MM cells mainly depend on ASCT2 for glutamine transport
On the basis of the gene expression profiling data, we focused our attention on the transporters potentially involved in Gln transport in HMCLs. Preliminarily, we excluded that SN1 or SN2 played a significant role in Gln influx in HMCLs. Although SN2 seems more expressed than SN1 in HMCLs, the overall contribution of the two systems to Gln influx was at best marginal, since lithium did not appreciably stimulate the uptake of Gln in the absence of sodium ( Figure S5 ). Also ATB 0,+ did not seem to contribute to Gln uptake in HMCLs, since the expression of SLC6A14 was exceedingly low compared to human airway Calu-3 cells used as a positive control, and, consistently, the preferential substrate D-Ser did not affect significantly Gln influx in MM cells.
( Figure S5 ).
On the contrary, SNAT1, ASCT2 and LAT1 were clearly expressed in all the HMCLs tested at both mRNA ( Figure 6A ) and protein levels ( Figure 6B ). The contribution of these transporters to Gln uptake was estimated in RPMI 8226 cells assessing the effects of amino acid analogues (MeAIB, GPNA and BCH), which work as preferential inhibitors of Gln uptake through, respectively, SNAT1, ASCT2 and LAT1 ( Figure 6C ). Only GPNA caused a marked inhibition of Gln uptake (-60%)
For personal use only. on July 26, 2016. by guest www.bloodjournal.org From ( Figure 6C ). The possibility that ASCT2 inhibition could be due to the products of GPNA hydrolysis glutamate and p-nitrophenol has been excluded, demonstrating that, at concentrations markedly larger than those expected during the assay period, the two compounds are without significant effects on Gln uptake ( Figure S6 ). ASCT2 expression was also examined in lysates from CD138 + cells of SMM and MM patients ( Figure 6D ). The transporter was detected in all the samples, and a trend of higher transporter expression was found in R-MM ( Figure 6D ). ASCT2 mRNA was also expressed by normal PCs at similar level of CD138 + cells obtained from patients with monoclonal gammopathies (data not shown).
The activity of ASCT2 is needed for MM growth
To evaluate the effects of Gln transporters on MM cell growth, the transport inhibitors were added to the culture medium of MM cells at the same concentrations used for the inhibition of Gln uptake ( Figure 7A ). GPNA had the largest growth inhibitory effect, roughly corresponding to a 70%-loss of cell viability compared with untreated control. Also BCH produced a marked decrease in MM cell viability (>50%), while the SNAT1 inhibitor MeAIB produced only a minimal effect.
To assess the effects of ASCT2 silencing on MM cell viability, a lentiviral vector was employed to transfect RPMI 8226 and JJN3 cells with an anti-SLC1A5 shRNA. A marked repression (>80%) of the transporter expression was obtained at both mRNA and protein level in silenced cells compared with cells transfected with the scramble control ( Figures 7B and 7C ). Gln influx was substantially lower in ASCT2-silenced than in scramble-transfected cells ( Figure 7D ). Moreover, the portion of Gln transport inhibited by GPNA was markedly smaller in ASCT2-silenced than in control cells, indicating that the different transport rates were effectively due to ASCT2 silencing. Indeed, while 2-OG easily supplies the intracellular Glu pool, the conversion of Glu to Gln is still prevented in MM cells by the absence of GS. Consequently, all the pathways that exhibit an absolute requirement for Gln will be severely hampered if a GS-negative MM cell is incubated under Gln-free conditions. Thus, human MM cells present a thus far unknown association between signs of Gln addiction and lack of expression of GS, two features that synergistically increase the dependence of MM cells upon extracellular Gln.
Consistently, HMCLs are more sensitive to E. chrysanthemi ASNase than to the E. coli enzyme.
While the two enzymes have comparable asparaginolytic activities, they differ as far as Gln hydrolysis is concerned, with the Erwinia enzyme endowed with a ten-fold higher activity.
Interestingly, the five HMCLs tested exhibited comparable IC 50 values for Erwinia ASNase, although they express Asparagine Synthetase at different levels. Moreover, ASNase caused a massive depletion of intracellular Gln but not of leucine ( Figure S3 ), while markedly inhibited mTOR activity ( Figure S4 ). However, rapamycin had much smaller effects on cell viability than ASNase ( Figure S4 ). Collectively, these data suggest that the hydrolysis of extracellular Gln, followed by the depletion of the intracellular Gln pool, is the prevalent mechanism of the antimyeloma activity exhibited by ASNase.
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These considerations highlight the critical importance that Gln transport assumes for MM cells, as suggested by the changes in gene expression across the progression of human PC dyscrasias.
Many transporters are potentially involved in Gln transport. 16, 54 However, the contribution of ATB 0,+ (SLC6A14), SN1 (SLC38A3) and SN2 (SLC38A5), known to interact with Gln in other cell models, 16, 54 did not appear important ( Figure S5 ). Three other transporters, LAT1, SNAT1 and ASCT2, showed increased expression during MM progression, suggesting that the affirmation of the neoplastic clone may require a growing supply of the amino acid through their operation. The relative contribution of each transporter to the uptake depends on several factors, the most important of which is the affinity towards Gln. 16 For this reason, the discrimination of transporter contribution to Gln uptake in MM cells has been performed at a concentration of Gln comparable to that present in human plasma. Under these conditions, ASCT2, estimated from the portion of uptake inhibited by GPNA, accounts for most of Gln influx, with SNAT1 and LAT1 restricted to minor roles. Consistently, GPNA suppressed MM cell viability. However, growth inhibition by the LAT1 inhibitor BCH was much larger than its effect on Gln uptake. This apparent anomaly may be explained considering that LAT1 also mediates the influx of many essential amino acids.
After showing that also ASCT2 silencing in vitro had significant inhibitory effects on MM cell growth in two different HMCLs, we confirmed these results with a xenograft model, although tumor growth inhibition was only partial. This result, comparable to data obtained with similar approaches in other human cancer models, 15, 23, 27 suggests that, when faced with scarce Gln fluxes from the extracellular compartment, MM cells can adopt escaping strategies based on the operation of other transporters. A good candidate could be the SNAT1 transporter, which, although found overexpressed in the genome-wide expression analysis during MM progression and nicely expressed in HMCLs, seems to account for a very minor portion of Gln uptake under control (Gln repleted) conditions. SLC7A11 gene has been also found overexpressed in MM cells. This gene encodes for xCT, an important transporter needed for exchanging intracellular Glu and extracellular cystine, which is involved in the cell response to oxidative stress. 55 Finally, our data indicate that blocking Gln uptake could be, possibly in association with other approaches, a suitable target to inhibit MM cell growth as also reported for other haematological
For personal use only. on July 26, 2016 . by guest www.bloodjournal.org From malignancies. 23, 24, 27 In line with this hypothesis, we show that bortezomib increased the cytotoxic effect of E. chrysanthemi ASNase as previously reported for acute leukemia cells. 56 Others recently showed that CB-839 blocks MM growth and synergized with pomalidomide in preclinical model, 57 and a phase I trial with CB-839 in patients with R-MM is currently under investigation. 58 Moreover, it has been recently reported that Gln withdrawal enhanced MM cell sensitivity to BH3 mimetics venetoclax (ABT-199), a new anti-myeloma drug currently under investigation 59 , and that ritonavir increases the Gln reliance of MM cells. 60 Overall, these data and our results suggest that Gln addiction and uptake could be a potential new therapeutic strategy in MM patients. 
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